Nexiva clinical trial

0

Intravenous literature: McNeill, E.E., Hines, N.L. and Phariss, R. (2009) A Clinical Trial of a New All-in-One Peripheral-Short Catheter. Journal of the Association for Vascular Access. 14(1), p.46-51.

Abstract:

The objectives of this survey were to: 1) understand current peripheral IV stabilization practices within our hospital and 2) evaluate the use of a new closed IV catheter system with a built-in stabilization platform. All medical-surgical patients within an 851-bed acute care hospital with peripheral-short catheters were evaluated within a 3-day period for catheter securement, dwell time, and signs of complications. Additionally, catheter restart data were collected from a renal telemetry unit for 2 weeks. Catheter and dressing protocols were then standardized to a new catheter system with a built-in stabilization platform (Nexivaâ„¢ Closed Catheter System) and an absorbent transparent dressing (SorbaView 2000). After a 2-week trial of the new protocol, catheters were again evaluated for securement and restart data were again collected from the renal telemetry unit. Staff nurse (N = 42) opinions on the new catheter system and dressing combination were sought, as well as a vote on willingness to change to the new catheter system and dressing. Results demonstrate improvement in catheter stabilization (out to 96 hours of dwell-time), decreased restarts, a high clinical preference for the new catheter/dressing system, and a high willingness to convert to the new system. Results indicate that the new closed IV catheter system with a built-in stabilization platform and the transparent absorbent dressing evaluated in this survey may help to improve catheter securement and increase dwell-time. Research studies utilizing more rigorous randomized, controlled comparisons are warranted.

More IV news at IVTEAM

Share.

Comments are closed.

Free Email Updates
Join 5.5K IVTEAM members. Subscribe now and be the first to receive all the latest free updates from IVTEAM!
100% Privacy. We don't spam.